NCT05567510View on ClinicalTrials.gov

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

December 27, 2022

Study Completion Date

December 27, 2022

Conditions
Healthy Participants
Interventions
DRUG

BMS-986369

Specified dose on specified days

Trial Locations (1)

53704-2526

Labcorp Clinical Research Unit - Madison, Madison

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05567510 - A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants | Biotech Hunter | Biotech Hunter